A client developing a new therapy sought to prioritize the indication for clinical development with the highest likelihood of technical and commercial success.
Task
Rank indication options by relative scientific rationale, competitive density, most-likely market evolution and addressable patient populations.
Action
Leveraged our scientific expertise to contextualize lessons learned from technically-analogous approaches, highlighting challenges, inflection points in the field and data gaps.
Curated historical proof-of-concept data.
Concisely conveyed competitive density and frontrunners in each indication of interest, along with the most likely market evolution.
Tapped into our primary intel network to pinpoint key areas of unmet need, and addressable patient populations.
Defined entry opportunities and challenges for top indications and framed these in terms of the client’s in-house assets and capabilities.
Developed a comprehensive plan for continuous CI monitoring, including fast-turnaround email alerts that frame new developments in the context of our current narrative and shared assumptions.
Results
Based on our engagement, the client was able to prioritize two specifically-defined patient populations where they have the best chance of addressing unmet need and gaining market adoption with their technology. The client used our insights to communicate a defensible rationale and win confidence with investors and shareholders.
Identified the unmet need
Established the rationale
Won confidence with investors
Selected the Optimal
Patient Population
No items found.
Please note: images are for illustrative purposes only.
Related Case Study
Steering a Go/No-Go Decision for Clinical Development
By clicking "Accept cookies", you agree to storing cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our privacy policy.
By clicking 'Accept all cookies', you agree to storing cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our privacy policy.
